Tenderwize
Back to tender search

Rivaroxaban (ATC B01AF01)

AOK - Die Gesundheitskasse in Hessen·Bad Homburg, Germany·Deadline Feb 01, 2027 · 160 days left·Open·Supplies
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)

5/100

Opportunity Score

High riskLow complexity
SuppliesOpen
Why this score?

Opportunity

5 / 100

Complexity

20 / 100

Risk factors

The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...

No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Weak opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclude non-exclusive discount agreements for finished medicinal products (Open House model).
  • Only specified active ingredient: Rivaroxaban (ATC B01AF01) – but this lot is cancelled.
Show full summary

This is an Open House model (non-exclusive discount agreements under §130a Abs. 8 SGB V) for finished medicinal products. The only listed lot (Rivaroxaban) is being cancelled as of 30 September 2025, with no new contracts. The overall submission deadline is 1 February 2027, but electronic submission is not allowed (email submission mentioned in XML notice). No estimated value, award criteria, or detailed eligibility criteria are provided. The tender appears to be a correction of a previous notice.

Risks

The only lot (Rivaroxaban) is cancelled. No new contracts will be concluded under this notice for that active ingredien...

No estimated value, award criteria, or detailed eligibility criteria. This makes it impossible to assess the value or c...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Contractors must be able to supply finished medicinal products with specified active ingredients.
  • Agreements are non-exclusive and follow the Open House model.
  • Contracts can be terminated early if AOK Hessen conducts an exclusive tender for the same active ingredients.

Award Criteria

Lot 1

No award criteria specified for this lot.

Buyer

Location

Bad Homburg, DEU

Website

www.aok.de

Identifier

DE114110216

Activity

Health

Lots (1)

LOT-0001

Rivaroxaban (ATC B01AF01)

This lot is cancelled as of 30 September 2025. No contracts will be concluded. A new procedure will be published. Scope: pharmaceutical product Rivaroxaban.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Mar 2025 - Mar 2027

Category

Pharmaceutical products

Award Criteria

No award criteria specified for this lot.

Procurement Details

Publication date
20 Aug 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
546345-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3